Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

DSM staff profile

Dr Michael Tatley

PositionSenior Research Fellow
DepartmentDepartment of Preventive and Social Medicine
QualificationsMB ChB(CapeTown) FFCM(SA)
Research summaryMonitoring adverse reactions medicines

Research

Director of the New Zealand Pharmacovigilance Centre

The New Zealand Pharmacovigilance Centre consists of the Centre for Adverse Reactions Monitoring (CARM) and the The Intensive Medicines Monitoring Programme (IMMP).

Adverse reaction reporting is an important component of New Zealand's pharmacovigilance activities. The Centre for Adverse Reactions Monitoring (CARM) in Dunedin is New Zealand's national monitoring centre for adverse reactions. It collects and evaluates spontaneous reports of adverse reactions to medicines, vaccines, herbal products and dietary supplements from health professionals in New Zealand. Currently the CARM database holds over 50 000 reports and provides New Zealand-specific information on adverse reactions to these products, and serves to support clinical decision making when unusual symptoms are thought to be therapy related.

The Intensive Medicines Monitoring Programme undertakes prospective, observational, cohort studies on selected new medicines. These are aimed at measuring the incidence of adverse reactions, their characterisation, the early identification of previously unrecognised reactions and the construction of a risk profile for each medicine. The results are reported to the Ministry of Health and the health professions. It has a considerable international reputation.

Publications

Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y

Savage, R. L., Castellano, M., & Tatley, M. V. (2017). International reports of unexpected low plasma concentrations of dabigatran suggest that more frequent measurements will add value. Seminars in Thrombosis & Hemostasis, 43(6), 635-638. doi: 10.1055/s-0037-1603361

Harrison-Woolrych, M., Tatley, M., & Kunac, D. (2014). Pharmacovigilance in New Zealand. In E. B. Andrews & N. Moore (Eds.), Mann's pharmacovigilance. (3rd ed.) (pp. 291-294). Chichester, UK: Wiley Blackwell. doi: 10.1002/9781118820186.ch16a

Kunac, D. L., Tatley, M. V., & Seddon, M. E. (2014). A new web-based Medication Error Reporting Programme (MERP) to supplement pharmacovigilance in New Zealand: Findings from a pilot study in primary care. New Zealand Medical Journal, 127(1401). Retrieved from http://www.nzma.org.nz/journal

Holst, J., Oster, P., Arnold, R., Tatley, M. V., Næss, L. M., Aaberge, I. S., … Black, S. (2013). Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future. Human Vaccines & Immunotherapeutics, 9(6), 1241-1253. doi: 10.4161/hv.24129

Authored Book - Research

Ministry of Health, including Chambers, S., Jennings, L., & Tatley, M. (2006). Immunisation Handbook 2006. Wellington, New Zealand: Ministry of Health, 455p.

^ Top of page

Chapter in Book - Research

Harrison-Woolrych, M., Tatley, M., & Kunac, D. (2014). Pharmacovigilance in New Zealand. In E. B. Andrews & N. Moore (Eds.), Mann's pharmacovigilance. (3rd ed.) (pp. 291-294). Chichester, UK: Wiley Blackwell. doi: 10.1002/9781118820186.ch16a

^ Top of page

Journal - Research Article

Kunac, D. L., Tatley, M. V., & Seddon, M. E. (2014). A new web-based Medication Error Reporting Programme (MERP) to supplement pharmacovigilance in New Zealand: Findings from a pilot study in primary care. New Zealand Medical Journal, 127(1401). Retrieved from http://www.nzma.org.nz/journal

Holst, J., Oster, P., Arnold, R., Tatley, M. V., Næss, L. M., Aaberge, I. S., … Black, S. (2013). Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future. Human Vaccines & Immunotherapeutics, 9(6), 1241-1253. doi: 10.4161/hv.24129

Kunac, D. L., & Tatley, M. V. (2011). Detecting medication errors in the New Zealand Pharmacovigilance Database: A retrospective analysis. Drug Safety, 34(1), 59-71. doi: 10.2165/11539290-000000000-00000

Tatley, M. V., Kunac, D. L., McNicholas, A., Zhou, L., Ballantyne, S., Ashton, J., … Reid, S. (2008). The Intensive Vaccines Monitoring Programme (IVMP): An electronic system to monitor vaccine safety in New Zealand. Vaccine, 26(22), 2746-2752. doi: 10.1016/j.vaccine.2008.03.017

Kunac, D. L., Harrison-Woolrych, M., & Tatley, M. V. (2008). Pharmacovigilance in New Zealand: The role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. New Zealand Medical Journal, 121(1283). Retrieved from http://journal.nzma.org.nz/journal/121-1283/3286/content.pdf

McNicholas, A., Galloway, Y., Stehr-Green, P., Reid, S., Radke, S., Sexton, K., … Tatley, M., … O'Hallahan, J. (2007). Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Human Vaccines, 3(5), 196-204.

Tatley, M., & Savage, R. (2007). Psychiatric adverse reactions with statins, fibrates and ezetimibe: Implications for the use of lipid-lowering agents. Drug Safety, 30(3), 195-201.

Tatley, M. V. (2002). The monitoring of adverse events following immunisation. New Zealand Medical Journal, 115(1165).

Tatley, M. (2002). Pulmonary reactions with nitrofurantoin. Medsafe Prescriber Update, 23(2), 24-25.

Zwarenstein, M., Schoeman, J. H., Vandule, C., Lombard, C. J., & Tatley, M. (1998). Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet, 352(9137), 1340-1343.

^ Top of page

Journal - Research Other

Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y

Savage, R. L., Castellano, M., & Tatley, M. V. (2017). International reports of unexpected low plasma concentrations of dabigatran suggest that more frequent measurements will add value. Seminars in Thrombosis & Hemostasis, 43(6), 635-638. doi: 10.1055/s-0037-1603361

Kunac, D., Tatley, M. V., Grimwood, K., & Reith, D. M. (2012). Active surveillance of serious adverse drug reactions in New Zealand children. Archives of Disease in Childhood, 97(8), 761-762. doi: 10.1136/archdischild-2011-301457

Tatley, M. (2009). Monitoring of generic medicines and brand changes. Best Practice Journal, (July), 18-20.

Barnes, J., & Tatley, M. (2007). Scant reporting on CAMs safety in NZ. Pharmacy Today, (February), 6.

Savage, R., & Tatley, M. (2004). Myopathy with statins: Check CK levels and interactions. Prescriber Update, 25(1), 4-5.

Zwarenstein, M., Shoeman, J. H., Vundule, C., Lombard, C. J., & Tatley, M. V. (2000). A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. International Journal of Tuberculosis & Lung Disease, 4(6), 550-554.

More publications...